The company announced in November that it plans to offer customers a generic version of liraglutide, an older GLP-1 weight loss drug, this year
[4] For patients taking Mounjaro, current evidence does not show a direct interaction with tirzepatide or consistent adverse glycaemic effects from artificial sweeteners, though individual variability in appetite response may occur
Semaglutide and Tirzepatide Both GLP-1 receptor agonists have been studied in metabolic research
Your gut anticipates this high level of energy, but when it doesn't arrive (artificial sweeteners have no calories), your gut doesn't utilize the food efficiently
Hormonal optimization can support the body composition goals that keto and GLP-1 target, and the interactions are generally favorable
Tirzepatide was initially approved for type 2 diabetes (Mounjaro), and it is now also approved for long-term weight loss in adults with obesity or overweight with weight-related health conditions (Zepbound)